Nuvation Bio Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUVB research report →
Range $10 – $21
Price Chart
About the company
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6.
- CEO
- David T. Hung
- IPO
- 2020
- Employees
- 310
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on NUVB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.34B
- P/E
- -9.58
- Fwd P/E
- 7.73
- PEG
- -0.20
- P/S
- 6.60
- P/B
- 5.83
- EV/EBITDA
- -15.30
- Div Yield
- 0.00%
- Gross Margin
- 90.64%
- Op Margin
- -61.17%
- Net Margin
- -67.38%
- ROE
- -49.11%
- ROIC
- -17.56%
Latest fiscal year · YoY change
- Revenue
- $62.90M+699.0%
- Gross Profit
- $54.46M+6750.3%
- Op Income
- $-213,064,000
- Net Income
- $-204,627,000+64.0%
- EPS
- $-0.60+71.6%
- OCF Growth
- -33.0%
- FCF Growth
- -33.1%
- 52W High
- $9.75
- 52W Low
- $3.71
- 50D MA
- $4.91
- 200D MA
- $5.29
- Beta
- 1.73
- RSI (14)
- 31
- Avg Volume
- 5.23M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nuvation Bio delivered $45 million of Q3 revenue, with IBTROZI driving strong growth and management reiterating confidence in long-term ROS1 leadership and safusidenib’s development path.· November 4, 2026
- Q3 total revenue was $45 million, led by $27.5 million of U.S. IBTROZI net product revenue and $17.5 million of collaboration/license revenue.
- IBTROZI net U.S. product revenue rose 18% sequentially, with about 160 new patients starting treatment and more than 60% of first-line new starts.
- Management said IBTROZI is now the leading ROS1 TKI in total active patients across all lines and maintains leadership in first-line starts.
- Safusidenib got FDA Fast Track designation, and management said it is on track to have all 4 studies enrolling in the coming months.
- Cash and marketable securities were $663.4 million as of September 30, 2026, and the company said it still believes it has enough capital to reach profitability.
For Q3 2026, total revenue was $45 million, including $27.5 million of IBTROZI net U.S. product revenue and $17.5 million of collaboration and license revenue. For the first 9 months of 2026, total revenue was $159.9 million, including $69.2 million of IBTROZI product revenue and $90.7 million of collaboration and license revenue. Gross-to-net deductions were approximately 30% in the quarter, and operating expenses totaled $75.2 million, including R&D of $32.7 million and SG&A of $42.6 million. Cash, cash equivalents and marketable securities were $663.4 million at September 30, 2026. Looking ahead, management said gross-to-net should remain generally stable, expects no material change in spending patterns for the remainder of the year, continues to expect an approximately $30 million milestone if Europe approval comes in the first half of next year, and reiterated that it believes it has sufficient capital to reach profitability.
David Hung’s tone was confident and expansive, centered on IBTROZI as the company’s commercial foundation and safusidenib as a second growth engine. He emphasized that IBTROZI’s 90% ORR, 50-month median DOR, 50-month median PFS and lack of a CNS warning support durable first-line adoption, while also saying the launch compares favorably with prior rare lung cancer launches. On safusidenib, he highlighted Fast Track status, the updated development plan, and the expectation of more meaningful data next year and beyond, plus a year-end update on the DDC platform.
Philippe Sauvage framed the quarter as one of disciplined investment and improving self-funding dynamics. He said gross-to-net was about 30% and should stay generally stable, operating expenses were $75.2 million, and the business continues to invest in TRUST, safusidenib and commercialization while not expecting material spending pattern changes for the rest of the year. He also noted $7.7 million of revenue came from milestone and royalty payments, highlighted the expected approximately $30 million Europe milestone, and said the company believes its $663.4 million cash balance and current operating plan are sufficient to reach profitability.
Analysts focused heavily on safusidenib timing, asking about enrollment, 2027 readouts, tumor growth rate, and whether Grade 3 oligodendroglioma or post-vorasidenib could read out first. Management said it would give more enrollment color later, reiterated that the response studies could begin showing responses in 2027, and argued that tumor growth rate may be an important future endpoint even though FDA acceptance is not assured. On IBTROZI, questions centered on the quarter’s softer new patient starts, competition from repotrectinib and zidesamtinib, and the size of the remaining first-line opportunity; management attributed the market softness to normal lumpiness in an ultra-rare disease, said IBTROZI is still gaining share, and stressed testing expansion and longer duration of therapy as key growth drivers.
The call supported a bull case that IBTROZI is becoming a durable ROS1 franchise with strong share, long time on therapy and continued patient accumulation. Management said the drug has the leading active-patient share, more than 60% of first-line starts, and a clinical profile they believe can sustain adoption even as competition increases. Safusidenib also adds upside, with Fast Track status, encouraging long-term data and multiple shots at data readouts across different glioma settings.
The main bear case is that IBTROZI’s growth may be lumpy because ROS1 is an ultra-rare market, and management acknowledged a roughly 15% decline in overall new patient starts across the market in the quarter. There is also clear competitive pressure ahead, including questions about future frontline entrants like zidesamtinib and the possibility that more patients shift among ROS1 TKIs. On safusidenib, timelines are still long for some pivotal studies, FDA acceptance of tumor growth rate is uncertain, and management noted that some readouts may not come until 2029 or later.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.0%
- Shares Outstanding
- 352.02M
- Float Shares
- 253.34M
of shares held by institutions
251 13F filers
Buy/sell ratio 0.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 52.67M | ▲ 438.19K |
| Blackrock, Inc. | 28.92M | ▲ 1.29M |
| Decheng Capital LLC | 25.95M | 0 |
| Vanguard Group Inc | 15.56M | ▲ 101.01K |
| Vanguard Capital Management LLC | 12.15M | ▲ 233.39K |
| Omega Fund Management, LLC | 8.08M | 0 |
| Laurion Capital Management LP | 7.70M | ▼ 122.74K |
| State Street Corp | 7.60M | ▲ 225.41K |
| Geode Capital Management, LLC | 6.45M | ▲ 201.87K |
| Duquesne Family Office LLC | 4.54M | 0 |
| American Century Companies Inc | 4.52M | ▲ 19.40K |
| Jones Hill Capital LP | 4.49M | ▲ 4.49M |
Held by 249 ETFs
Biggest fund positions in NUVB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 19, 26 | Hattersley Gary | other | 100,000 |
| Aug 19, 26 | Hattersley Gary | other | 100,000 |
| Aug 19, 26 | Hattersley Gary | sell | 100,000 |
| Jul 15, 26 | Sauvage Philippe | other | 39,999 |
| Jul 15, 26 | Sauvage Philippe | other | 1 |
| Jul 15, 26 | Sauvage Philippe | other | 1 |
| Jul 15, 26 | Sauvage Philippe | other | 39,999 |
| Jun 23, 26 | Markel Stacy | other | 90,380 |
| Jun 23, 26 | Markel Stacy | other | 34,620 |
| Jun 23, 26 | Markel Stacy | other | 34,620 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NUVB coverage
Recent articles, reports, and earnings notes.
No research on NUVB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NUVB report →Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
gurufocus.com · Nov 16
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
prnewswire.com · Nov 16
ACT Capital Partners L.P. Buys 579,500 Shares of Nuvation Bio Inc. $NUVB
defenseworld.net · Nov 15
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 10
Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients
seekingalpha.com · Nov 9
What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call
marketbeat.com · Nov 8
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.